TIGIT, as the only downregulated immune checkpoint in the high-risk group, is primarily expressed on T cells and NK cells, which can inhibit anti-tumor immunity by impairing T cell functions, preventing NK cell-mediated lysis, and enhancing the suppressive activity of regulatory T cells [55]. This evidence concerns the gene TIGIT and neoplasm.